The Relative Role of Lymphocyte Granule Exocytosis versus Death Receptor-Mediated Cytotoxicity in Viral Pathophysiology

Por Smyth, Mark J., Trapani, Joseph A.
Publicado em 1998

Immune surveillance of tumors

Por Swann, Jeremy B., Smyth, Mark J.
Publicado em 2007

NKT cell adjuvants in therapeutic vaccines against hematological cancers

Por Mattarollo, Stephen R., Smyth, Mark J.
Publicado em 2013

Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression

Por Smyth, Mark J, Teng, Michele W L
Publicado em 2014

Fas Ligand-Mediated Lysis of Self Bystander Targets by Human Papillomavirus-Specific CD8(+) Cytotoxic T Lymphocytes

Por Smyth, Mark J., Krasovskis, Erika, Johnstone, Ricky W.
Publicado em 1998

DNAM-1: would the real natural killer cell please stand up!

Por Huntington, Nicholas D., Martinet, Ludovic, Smyth, Mark J.
Publicado no Oncotarget (2015)

α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis

Por Hayakawa, Yoshihiro, Rovero, Stefania, Forni, Guido, Smyth, Mark J.
Publicado em 2003

A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced Sarcomas

Por Crowe, Nadine Y., Smyth, Mark J., Godfrey, Dale I.
Publicado em 2002

Hypoxia-driven immunosuppression contributes to the pre-metastatic niche

Por Sceneay, Jaclyn, Parker, Belinda S., Smyth, Mark J., Möller, Andreas
Publicado em 2013

The anticancer effects of HDAC inhibitors require the immune system

Por West, Alison C, Smyth, Mark J, Johnstone, Ricky W
Publicado em 2014

IFN type III: in vivo NK cell response

Por Souza-Fonseca-Guimaraes, Fernando, Young, Arabella, Smyth, Mark J.
Publicado no Oncotarget (2015)

Interleukin 2 Receptor Signaling Regulates the Perforin Gene through Signal Transducer and Activator of Transcription (Stat)5 Activation of Two Enhancers

Por Zhang, Jin, Scordi, Irinoulla, Smyth, Mark J., Lichtenheld, Mathias G.
Publicado em 1999

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

Por O’Donnell, Jake S., Smyth, Mark J., Teng, Michele W. L.
Publicado no Genome Med (2016)

The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis

Por Smyth, Mark J., Krasovskis, Erika, Sutton, Vivien R., Johnstone, Ricky W.
Publicado em 1998

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies

Por Liu, Jing, Blake, Stephen J, Smyth, Mark J, Teng, Michele WL
Publicado no Clin Transl Immunology (2014)

New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape

Por Mittal, Deepak, Gubin, Matthew M, Schreiber, Robert D, Smyth, Mark J
Publicado no Curr Opin Immunol (2014)

The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects

Por West, Alison C., Christiansen, Ailsa J., Smyth, Mark J., Johnstone, Ricky W.
Publicado em 2012

Non-classical MHC Class I molecules regulating natural killer cell function

Por Smyth, Mark J., Sullivan, Lucy C., Brooks, Andrew G., Andrews, Daniel M.
Publicado em 2013

Classifying cancers based on T cell infiltration and PD-L1

Por Teng, Michele W. L., Ngiow, Shin Foong, Ribas, Antoni, Smyth, Mark J.
Publicado no Cancer Res (2015)

Natural Killer cell control of BRAF(V600E) mutant melanoma during targeted therapy

Por de Andrade, Lucas Ferrari, Ngiow, Shin Foong, Martinet, Ludovic, Smyth, Mark J
Publicado no Oncoimmunology (2015)